טוען...
Off-label use of rituximab in systemic lupus erythematosus: a systematic review
Considerable interest in the efficacy of rituximab (a monoclonal CD20 antibody) in patients with systemic lupus erythematosus (SLE) has been generated due to its unique mode of action, culminating in a series of randomized and open trials, and case reports. However, this use is off-license and two s...
שמור ב:
| הוצא לאור ב: | Clin Rheumatol |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer-Verlag
2010
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7102216/ https://ncbi.nlm.nih.gov/pubmed/20155295 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10067-010-1387-5 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|